Published in J Clin Oncol on September 01, 2008
Beta-blocker use is associated with improved relapse-free survival in patients with triple-negative breast cancer. J Clin Oncol (2011) 2.90
Triple-negative breast cancers are increased in black women regardless of age or body mass index. Breast Cancer Res (2009) 2.23
Preventable Incidence and Mortality of Carcinoma Associated With Lifestyle Factors Among White Adults in the United States. JAMA Oncol (2016) 2.22
Ki67, chemotherapy response, and prognosis in breast cancer patients receiving neoadjuvant treatment. BMC Cancer (2011) 1.83
Obesity and weight change in relation to breast cancer survival. Breast Cancer Res Treat (2010) 1.60
Lifestyle as risk factor for cancer: Evidence from human studies. Cancer Lett (2010) 1.35
Metabolic syndrome and triple-negative breast cancer: a new paradigm. Int J Breast Cancer (2011) 1.10
Weight gain, metabolic syndrome, and breast cancer recurrence: are dietary recommendations supported by the data? Int J Breast Cancer (2012) 1.09
Association of angiopoietin-2, C-reactive protein and markers of obesity and insulin resistance with survival outcome in colorectal cancer. Br J Cancer (2010) 0.97
Obesity and cancer: mechanistic insights from transdisciplinary studies. Endocr Relat Cancer (2015) 0.96
Obesity and cancer treatment: weighing the evidence. J Clin Oncol (2008) 0.95
The relationship between body composition and response to neoadjuvant chemotherapy in women with operable breast cancer. Oncologist (2012) 0.92
Effect of obesity on outcomes after autologous hematopoietic stem cell transplantation for multiple myeloma. Biol Blood Marrow Transplant (2011) 0.90
Weight change and its correlates among breast cancer survivors. Nutr Cancer (2011) 0.90
Obesity or overweight is associated with worse pathological response to neoadjuvant chemotherapy among Chinese women with breast cancer. PLoS One (2012) 0.89
Obesity Correlation With Metastases Development and Response to First-Line Metastatic Chemotherapy in Breast Cancer. Clin Med Insights Oncol (2015) 0.87
Mechanisms linking excess adiposity and carcinogenesis promotion. Front Endocrinol (Lausanne) (2014) 0.86
Ethnic disparities in adherence to breast cancer survivorship surveillance care. Cancer (2013) 0.86
Epithelial-to-mesenchymal transition in breast cancer: a role for insulin-like growth factor I and insulin-like growth factor-binding protein 3? Breast Cancer (Dove Med Press) (2015) 0.85
Evaluation of chemotherapy-induced severe myelosuppression incidence in obese patients with capped dosing. J Oncol Pract (2011) 0.84
Clinical and genetic predictors of weight gain in patients diagnosed with breast cancer. Br J Cancer (2013) 0.83
Impact of weight change during neoadjuvant chemotherapy on pathologic response in triple-negative breast cancer. Cancer Med (2015) 0.81
Oncogenic role of leptin and Notch interleukin-1 leptin crosstalk outcome in cancer. World J Methodol (2016) 0.80
The impact of overweight and obesity on breast cancer: data from Switzerland, so far a country little affected by the current global obesity epidemic. Gland Surg (2014) 0.79
Marginal effects of glucose, insulin and insulin-like growth factor on chemotherapy response in endothelial and colorectal cancer cells. Oncol Lett (2013) 0.79
Obesity and outcomes in patients treated with chemoradiotherapy for esophageal carcinoma. Dis Esophagus (2013) 0.77
Association of Body Mass Index Changes during Neoadjuvant Chemotherapy with Pathologic Complete Response and Clinical Outcomes in Patients with Locally Advanced Breast Cancer. J Cancer (2015) 0.76
Metabolic syndrome in breast cancer. Gland Surg (2013) 0.76
Body mass index is not associated with treatment outcomes of breast cancer patients receiving neoadjuvant chemotherapy: korean data. J Breast Cancer (2012) 0.76
Impact of body fat distribution on neoadjuvant chemotherapy outcomes in advanced breast cancer patients. Cancer Med (2015) 0.75
Obesity Suppresses Estrogen Receptor Beta Expression in Breast Cancer Cells via a HER2-Mediated Pathway. PLoS One (2015) 0.75
Impact of race, ethnicity, and BMI on achievement of pathologic complete response following neoadjuvant chemotherapy for breast cancer: a pooled analysis of four prospective Alliance clinical trials (A151426). Breast Cancer Res Treat (2016) 0.75
Adjuvant Aromatase Inhibitors in Early Breast Cancer May Not Increase the Risk of Falls. J Bone Rep Recomm (2016) 0.75
Weight loss after breast cancer diagnosis may not improve prognosis. J Clin Oncol (2009) 0.75
Targeting the COX-2 Pathway to Improve Therapeutic Response in the Obese Breast Cancer Patient Population. Curr Pharmacol Rep (2015) 0.75
Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer. N Engl J Med (2011) 13.74
Response to neoadjuvant therapy and long-term survival in patients with triple-negative breast cancer. J Clin Oncol (2008) 11.03
PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patients. Cancer Cell (2004) 10.89
Metformin and pathologic complete responses to neoadjuvant chemotherapy in diabetic patients with breast cancer. J Clin Oncol (2009) 10.18
Breast cancer molecular subtypes respond differently to preoperative chemotherapy. Clin Cancer Res (2005) 9.70
Prognostic and predictive value of the 21-gene recurrence score assay in postmenopausal women with node-positive, oestrogen-receptor-positive breast cancer on chemotherapy: a retrospective analysis of a randomised trial. Lancet Oncol (2009) 9.39
Future of cancer incidence in the United States: burdens upon an aging, changing nation. J Clin Oncol (2009) 8.55
Genome-wide association study identifies five susceptibility loci for glioma. Nat Genet (2009) 7.62
Pharmacogenomic predictor of sensitivity to preoperative chemotherapy with paclitaxel and fluorouracil, doxorubicin, and cyclophosphamide in breast cancer. J Clin Oncol (2006) 7.24
Measurement of residual breast cancer burden to predict survival after neoadjuvant chemotherapy. J Clin Oncol (2007) 7.00
Cyclin E and survival in patients with breast cancer. N Engl J Med (2002) 6.44
Combating trastuzumab resistance by targeting SRC, a common node downstream of multiple resistance pathways. Nat Med (2011) 6.21
Circulating tumor cells: a novel prognostic factor for newly diagnosed metastatic breast cancer. J Clin Oncol (2005) 6.18
The HER-2 receptor and breast cancer: ten years of targeted anti-HER-2 therapy and personalized medicine. Oncologist (2009) 6.00
Characterization of a naturally occurring breast cancer subset enriched in epithelial-to-mesenchymal transition and stem cell characteristics. Cancer Res (2009) 5.68
Prognosis of women with metastatic breast cancer by HER2 status and trastuzumab treatment: an institutional-based review. J Clin Oncol (2009) 5.64
ERK promotes tumorigenesis by inhibiting FOXO3a via MDM2-mediated degradation. Nat Cell Biol (2008) 5.19
Mechanisms of disease: understanding resistance to HER2-targeted therapy in human breast cancer. Nat Clin Pract Oncol (2006) 4.91
Breast carcinoma in men: a population-based study. Cancer (2004) 4.88
In Support of a Patient-Driven Initiative and Petition to Lower the High Price of Cancer Drugs. Mayo Clin Proc (2015) 4.70
A genomic predictor of response and survival following taxane-anthracycline chemotherapy for invasive breast cancer. JAMA (2011) 4.63
Goserelin for ovarian protection during breast-cancer adjuvant chemotherapy. N Engl J Med (2015) 4.53
IKK beta suppression of TSC1 links inflammation and tumor angiogenesis via the mTOR pathway. Cell (2007) 4.48
Upregulation of CXCR4 is essential for HER2-mediated tumor metastasis. Cancer Cell (2004) 4.17
High risk of recurrence for patients with breast cancer who have human epidermal growth factor receptor 2-positive, node-negative tumors 1 cm or smaller. J Clin Oncol (2009) 4.05
Gene expression profiles in paraffin-embedded core biopsy tissue predict response to chemotherapy in women with locally advanced breast cancer. J Clin Oncol (2005) 4.03
Epidemiology of primary brain tumors: current concepts and review of the literature. Neuro Oncol (2002) 3.99
Overview of resistance to systemic therapy in patients with breast cancer. Adv Exp Med Biol (2007) 3.93
Projecting individualized absolute invasive breast cancer risk in African American women. J Natl Cancer Inst (2007) 3.93
Combination anastrozole and fulvestrant in metastatic breast cancer. N Engl J Med (2012) 3.86
Trastuzumab in the treatment of breast cancer. N Engl J Med (2005) 3.86
Bone imaging in metastatic breast cancer. J Clin Oncol (2004) 3.85
Weekly paclitaxel improves pathologic complete remission in operable breast cancer when compared with paclitaxel once every 3 weeks. J Clin Oncol (2005) 3.83
Prognostic factors that determine the long-term survival of patients with unresectable metastatic melanoma. Cancer Invest (2008) 3.69
Prognostic value of pathologic complete response after primary chemotherapy in relation to hormone receptor status and other factors. J Clin Oncol (2006) 3.58
Epidermal growth factor receptor cooperates with signal transducer and activator of transcription 3 to induce epithelial-mesenchymal transition in cancer cells via up-regulation of TWIST gene expression. Cancer Res (2007) 3.53
Recommendations from an international expert panel on the use of neoadjuvant (primary) systemic treatment of operable breast cancer: an update. J Clin Oncol (2006) 3.52
Mammography before diagnosis among women age 80 years and older with breast cancer. J Clin Oncol (2008) 3.49
Congestive heart failure in older women treated with adjuvant anthracycline chemotherapy for breast cancer. J Clin Oncol (2007) 3.46
Male breast cancer. Lancet (2006) 3.41
Breast cancer in men. Ann Intern Med (2002) 3.39
Long-term cardiac tolerability of trastuzumab in metastatic breast cancer: the M.D. Anderson Cancer Center experience. J Clin Oncol (2006) 3.34
A road map for efficient and reliable human genome epidemiology. Nat Genet (2006) 3.21
Residual risk of breast cancer recurrence 5 years after adjuvant therapy. J Natl Cancer Inst (2008) 3.17
Clinical and pathologic characteristics of patients with BRCA-positive and BRCA-negative breast cancer. J Clin Oncol (2008) 3.09
Use and outcomes of adjuvant chemotherapy in older women with breast cancer. J Clin Oncol (2006) 3.08
Estrogen receptor (ER) mRNA and ER-related gene expression in breast cancers that are 1% to 10% ER-positive by immunohistochemistry. J Clin Oncol (2012) 2.98
Atypical PKCiota contributes to poor prognosis through loss of apical-basal polarity and cyclin E overexpression in ovarian cancer. Proc Natl Acad Sci U S A (2005) 2.96
Risk of cardiac death after adjuvant radiotherapy for breast cancer. J Natl Cancer Inst (2005) 2.93
Genomic index of sensitivity to endocrine therapy for breast cancer. J Clin Oncol (2010) 2.91
Beta-blocker use is associated with improved relapse-free survival in patients with triple-negative breast cancer. J Clin Oncol (2011) 2.90
Determination of oestrogen-receptor status and ERBB2 status of breast carcinoma: a gene-expression profiling study. Lancet Oncol (2007) 2.90
Preclinical testing of clinically applicable strategies for overcoming trastuzumab resistance caused by PTEN deficiency. Clin Cancer Res (2007) 2.89
Acute and late onset cognitive dysfunction associated with chemotherapy in women with breast cancer. Cancer (2010) 2.88
Examination of mutations in BRAF, NRAS, and PTEN in primary cutaneous melanoma. J Invest Dermatol (2006) 2.87
Effect of primary tumor extirpation in breast cancer patients who present with stage IV disease and an intact primary tumor. Ann Surg Oncol (2006) 2.84
PIK3CA mutations associated with gene signature of low mTORC1 signaling and better outcomes in estrogen receptor-positive breast cancer. Proc Natl Acad Sci U S A (2010) 2.79
Phase II study of weekly docetaxel and trastuzumab for patients with HER-2-overexpressing metastatic breast cancer. J Clin Oncol (2002) 2.75
Is breast cancer survival improving? Cancer (2004) 2.73
High-dose chemotherapy with autologous stem-cell support as adjuvant therapy in breast cancer: overview of 15 randomized trials. J Clin Oncol (2011) 2.73
Nomograms to predict pathologic complete response and metastasis-free survival after preoperative chemotherapy for breast cancer. J Clin Oncol (2005) 2.69
Phase I and pharmacokinetic study of ABI-007, a Cremophor-free, protein-stabilized, nanoparticle formulation of paclitaxel. Clin Cancer Res (2002) 2.66
Incidence and outcome of BRCA mutations in unselected patients with triple receptor-negative breast cancer. Clin Cancer Res (2011) 2.64
Primary cutaneous apocrine carcinoma: a clinico-pathologic analysis of 24 cases. Am J Surg Pathol (2008) 2.58
EZH2 promotes expansion of breast tumor initiating cells through activation of RAF1-β-catenin signaling. Cancer Cell (2011) 2.54
PTEN, PIK3CA, p-AKT, and p-p70S6K status: association with trastuzumab response and survival in patients with HER2-positive metastatic breast cancer. Am J Pathol (2010) 2.52
Long-term complications associated with breast-conservation surgery and radiotherapy. Ann Surg Oncol (2002) 2.51
PI3K pathway mutations and PTEN levels in primary and metastatic breast cancer. Mol Cancer Ther (2011) 2.50
Molecular characterization of breast cancer with high-resolution oligonucleotide comparative genomic hybridization array. Clin Cancer Res (2009) 2.49
Specific mutations in the beta-catenin gene (CTNNB1) correlate with local recurrence in sporadic desmoid tumors. Am J Pathol (2008) 2.48
Inflammatory breast cancer: the disease, the biology, the treatment. CA Cancer J Clin (2010) 2.45
Preoperative therapy in invasive breast cancer: pathologic assessment and systemic therapy issues in operable disease. J Clin Oncol (2008) 2.43
Risk factors for joint symptoms in patients enrolled in the ATAC trial: a retrospective, exploratory analysis. Lancet Oncol (2008) 2.42
Frequency and risk factors associated with osteonecrosis of the jaw in cancer patients treated with intravenous bisphosphonates. J Bone Miner Res (2008) 2.42
Invasive lobular carcinoma classic type: response to primary chemotherapy and survival outcomes. J Clin Oncol (2005) 2.39